CLAIMS:

1. A crystalline form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, substantially free of other polymorphic forms of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate.

2. The crystalline form of claim **1**, wherein said crystalline form is anhydrous 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate ("Form I"), and characterized by having a melting point of about 253°C, and an aqueous solubility of about 8.3 mg/mL at 25°C.

3. The crystalline form of claim **1**, wherein said crystalline form is Form I, characterized by an X-ray powder diffraction (XRPD) pattern that comprises peaks at 10.0, 18.1, 18.6, 20.1, and 23.9 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation.

4. The crystalline form of claim **3**, wherein the XRPD pattern further comprises a peak at 20.5 degrees, ± 0.5 degrees, 2θ.

5. The crystalline form of claim **3** or **4**, wherein the XRPD pattern is substantially similar to the pattern of Figure 1.

6. The crystalline form of claim **1**, wherein said crystalline form is Form II, characterized by an XRPD pattern that comprises peaks at 4.2, 5.6, 8.4, 17.8, and 19.8 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation.

7. The crystalline form of claim **6**, wherein the XRPD pattern further comprises a peak at 12.7 degrees, ± 0.5 degrees, 2θ.

8. The crystalline form of claim **6** or **7**, wherein the XRPD pattern is substantially similar to the pattern of Figure 2.

9. The crystalline form of claim **1**, wherein said crystalline form is Form III, characterized by XRPD pattern that comprises peaks at 7.7, 10.7, 20.1, 23.7, and 24.3 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation.

10. The crystalline form of claim **9**, wherein the XRPD pattern further comprises peaks at 18.5 and 26.5 degrees, ± 0.5 degrees, 2θ.

11. The crystalline form of claim **9** or **10**, wherein the XRPD pattern is substantially similar to the pattern of Figure 3.

12. The crystalline form of claim **1**, wherein said crystalline form is Form IV, characterized by an XRPD pattern that comprises peaks at 18.5, 19.6, and 23.7 degrees, ± 0.5 degrees, 2θ, wherein said XRPD is made using Cu Kα radiation.

13. An amorphous form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate, characterized by having a melting point of about 240°C, and an aqueous solubility of about 7.1 mg/mL in water at 25°C ("Form V").

14. A pharmaceutical composition, comprising a solid form of any one of claims **1** to **13**, and a pharmaceutically acceptable carrier.

15. A method for making the Form I of any one of claims **2** to **5**, comprising:

contacting a solid form of 1-benzyl-N-(4-carbamimidoylbenzyl)-1H-pyrazole-4-carboxamide acetate with a solvent selected from the group consisting of methanol, ethanol, isopropanol, tetrahydrofuran, 2-methyl-tetrahydrofuran, anhydrous acetone, dichloromethane, diethyl ether, 3-methyl-1-butanol, and nitromethane, or a mixture thereof, for a period of time sufficient to produce Form I.

16. The crystalline form of any of claims **1** to **13**, having less than 5% by weight of any other polymorphic form.

17. The crystalline form of any one of claims **1** to **13**, having less than 1% by weight of any other polymorphic form.

18. Use of the crystalline form of any one of claims **1** to **13**, or the pharmaceutical composition of claim **14**, in the preparation of a medicament for treating of a plasma kallikrein-dependent disease or condition in a subject in need thereof.

19. The use of claim **18**, wherein the plasma kallikrein-dependent disease or condition is selected from the group consisting of:

diabetic macular edema, diabetic retinopathy, hereditary angioedema with C1 inhibitor deficiency, acute liver injury, inflammation, anaphylaxis, chemical-sensitized renal damage, ischemic stroke, hemorrhagic stroke, hypertension, vascular complications of hypertension, retinopathy, nephropathy, cerebrovascular edema, pulmonary hypertension, inflammation, pain, acute myocardial infarction, deep vein thrombosis, complications from fibrinolytic treatment, angina, angioedema, sepsis, arthritis, complications of cardiopulmonary bypass surgery, capillary leak syndrome, inflammatory bowel disease, diabetes, diabetic retinopathy, diabetic macular edema, diabetic nephropathy, diabetic neuropathy, age-related macular degeneration, retinal vein occlusions, brain edema, ischemia-reperfusion injury, cancer-related angiogenesis, asthma, anaphylaxis, and cerebrovascular complications of Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, Central Nervous System infections, and glioblastoma multiforme.